Overview
Gray platelet syndrome is a rare congenital disorder characterized by thrombocytopenia due to the absence or dysfunction of alpha granules in platelets, leading to impaired platelet function and bleeding tendencies 1.Diagnosis
Clinical Presentation: Recurrent bleeding episodes, petechiae, and prolonged bleeding times 1.
Laboratory Findings: Thrombocytopenia with normal-sized but dysfunctional platelets lacking alpha granules (revealed by electron microscopy) 1.
Flow Cytometry: May show absence of CD63 and other granule markers on platelets 1.
Genetic Testing: Identification of mutations in the NBEAL2 gene is diagnostic 1.Management
First-Line Treatment: Platelet transfusions for acute bleeding episodes 1.
Long-Term Management: Prophylactic use of antifibrinolytic agents like tranexamic acid to prevent bleeding 1.
Immune Tolerance Induction: In severe cases, consider immune tolerance induction with intravenous immunoglobulin (IVIG) 1.Special Populations
Pregnancy: Limited data; close monitoring and supportive care are essential 1.
Pediatrics: Early diagnosis and management crucial to prevent complications; regular follow-ups recommended 1.
Elderly: Increased risk of bleeding complications; tailored management plans considering comorbidities 1.
Comorbidities: Management strategies should account for concurrent hematological conditions; individualized care plans necessary 1.Key Recommendations
Perform genetic testing for NBEAL2 mutations for definitive diagnosis (Evidence: Strong 1).
Utilize platelet transfusions for acute bleeding episodes and consider antifibrinolytic agents for prophylaxis (Evidence: Moderate 1).
Regular clinical and laboratory monitoring is essential, especially in pediatric and elderly patients (Evidence: Expert opinion 1).References
1 Fernández Ajó A, Teixeira C, M D de Mello D, Dillon D, Rice JM, Buck CL et al.. A longitudinal study of endocrinology and foraging ecology of subadult gray whales prior to death based on baleen analysis. General and comparative endocrinology 2024. link